Connection

Michael Hallek to Immunotherapy

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Immunotherapy.
Michael Hallek
Connection Strength
0.681
Immunotherapy
  1. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 03 01; 131(9):955-962.
    View in: PubMed
    Score: 0.266
  2. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
    View in: PubMed
    Score: 0.229
  3. [Individualized Treatment of Chronic Lymphocytic Leukemia (CLL)]. Dtsch Med Wochenschr. 2018 09; 143(18):1318-1324.
    View in: PubMed
    Score: 0.070
  4. Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy. Cancer Immunol Res. 2017 09; 5(9):730-743.
    View in: PubMed
    Score: 0.065
  5. Management of unfit elderly patients with chronic lymphocytic leukemia. Eur J Intern Med. 2018 12; 58:7-13.
    View in: PubMed
    Score: 0.018
  6. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia. Br J Haematol. 2018 12; 183(5):727-735.
    View in: PubMed
    Score: 0.018
  7. Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.